PeptiDex
Research Blend Reference

CJC-1295 + Ipamorelin Blend

A research-supplier blend combining the GHRH analog CJC-1295 with the GH-secretagogue Ipamorelin, often paired in growth-axis research.

CJC-1295Ipamorelin
For research and educational purposes only. This page documents what a research-supplier blend contains and what the literature says about each component individually. Cross-referenced for research context — not a usage or combination recommendation. It is not medical advice, contains no amounts, ratios or schedules, and does not suggest that these compounds should be combined.

What the blend contains

The components recorded on the CJC-1295 + Ipamorelin Blend entry, exactly as listed. A component with its own PeptiDex entry links through to it.

CJC-1295GHRH analog (long-acting, with Drug Affinity Complex / DAC)IpamorelinGrowth-hormone secretagogue (GHRP) / ghrelin receptor agonist

Components at a glance

Reference table comparing CJC-1295, Ipamorelin on compound class, length, molecular weight and half-life.
AttributeCJC-1295Ipamorelin
Compound classGHRH analog (long-acting, with Drug Affinity Complex / DAC)Growth-hormone secretagogue (GHRP) / ghrelin receptor agonist
Length (amino acids)30 amino acids5 amino acids
Molecular weightApproximately 3647 g/mol (with DAC linker)711.9 g/mol
Half-lifeSubstantially extended vs native GHRH; reported on the order of days (approximately 6-8 days) due to albumin binding via DAC~2 hours (reported approximately 120 minutes)

“Not documented” means the PeptiDex entry records no value for that field. Nothing here is estimated.

Each component in the research literature

The 2 compounds below are this blend's documented components. Each section is that compound's own library entry — its class, its mechanism as described in the research literature, and the contexts it is studied in.

CJC-1295 — GHRH analog (long-acting, with Drug Affinity Complex / DAC)

A long-acting GHRH analog often referenced alongside Ipamorelin in research literature.

CJC-1295 is a GHRH-receptor agonist that stimulates pulsatile GH secretion from the pituitary. Its GHRH(1-29) backbone carries stabilizing amino-acid substitutions (e.g. at positions 2, 8, 15, 27) that resist DPP-4 degradation, and the DAC group forms a covalent bond with albumin, dramatically prolonging its action. This produces a sustained elevation of GH and IGF-1 rather than sharp discrete pulses.

Studied in these research contexts

Sustained stimulation of the GH/IGF-1 axis (early-phase clinical and preclinical)Body-composition researchInvestigation of long-acting GHRH analog pharmacokineticsStudies combining GHRH analogs with GHRPs

Ipamorelin — Growth-hormone secretagogue (GHRP) / ghrelin receptor agonist

A selective GH-secretagogue peptide studied in pulsatile GH-release research.

Ipamorelin is an agonist of the growth-hormone secretagogue receptor (GHS-R1a, the ghrelin receptor), mimicking ghrelin to stimulate GH release from the anterior pituitary. It acts on the pituitary and hypothalamus to promote a pulsatile release of growth hormone. Unlike some other GHRPs, it is reported to be highly selective, releasing GH without significantly stimulating ACTH, cortisol, or prolactin at effective doses.

Studied in these research contexts

Stimulation of endogenous growth-hormone secretion (preclinical)Investigational interest in GH-deficiency-related statesPreclinical studies on bone mineralization and body compositionInterest in appetite/gastric motility via ghrelin-receptor pathwayComparative selectivity studies among GHRPs

Mechanistic descriptions are quoted from each compound's own entry and reflect published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds. Listing a research area is not a claim of efficacy or a therapeutic indication.

Why these are co-studied

Cross-referenced for research context — not a usage or combination recommendation. Each note below is the research-context rationale recorded on the compounds' own library entries; follow a card for the full side-by-side comparison.

CJC-1295 + IpamorelinGHRH analog + GHRP combination is studied for synergistic amplification of GH pulses.

Frequently asked questions

Why is CJC-1295 studied together with ipamorelin?

CJC-1295 provides sustained GHRH-receptor stimulation while ipamorelin provides ghrelin-receptor (GHS-R) stimulation. The two pathways are synergistic, and the CJC-1295 + ipamorelin pairing is one of the most widely referenced GH-secretagogue research combinations.

What is CJC-1295 (with DAC)?

CJC-1295 is a synthetic long-acting analog of GHRH(1-29). This slug refers to the DAC (Drug Affinity Complex) version, which carries a maleimidopropionic acid linker that covalently binds serum albumin after injection, dramatically extending its circulating half-life to several days.

Why is ipamorelin commonly studied alongside a GHRH analog like CJC-1295?

Ipamorelin (a GHS-R agonist) and a GHRH analog such as CJC-1295 or sermorelin act on two different receptor pathways. Research protocols pair them because combined GHRH + GHRP stimulation produces a synergistic, amplified GH pulse greater than either compound alone.

What is ipamorelin and what class of compound is it?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (a ghrelin/GHS-R1a receptor agonist). It is studied as one of the most selective GHRPs, stimulating pulsatile GH release from the anterior pituitary with minimal effect on cortisol, prolactin, or ACTH in research models.

Answers are published on each compound's own PeptiDex entry. They describe individual compounds in research contexts; none of them describes using the compounds together.

Continue exploring